An internal letter from a senior official at the U.S. Food and Drug Administration has prompted renewed scrutiny of the government’s COVID-19 vaccination strategy for children — especially during the height of federal mandates.

Millions of Americans, including school-aged children, were strongly encouraged — and in some cases required — to receive the first-ever mRNA COVID-19 vaccines if they wished to keep their jobs, continue in-person schooling, dine in public, or visit vulnerable loved ones.

For much of the pandemic, federal health officials and major media outlets insisted the vaccines were “safe and effective,” pushing back aggressively against concerns about potential risks. Critics of the rapidly developed vaccines were often labeled misinformed or censored on major platforms.

However, according to reporting from multiple outlets — including the Washington Post — a recently disclosed FDA email indicates that federal scientists have identified a number of child deaths possibly linked to the vaccine.

Dr. Vinay Prasad, the FDA’s Chief Medical Officer and director at the Center for Biologics Evaluation and Research, briefed staff on Friday that career analysts in the Office of Biostatistics and Pharmacovigilance reviewed 96 pediatric deaths between 2021 and 2024.

Their conclusion: at least 10 of those deaths were likely, probable, or possibly related to post-vaccination events.

Prasad called the findings “a profound revelation,” writing that the current count is “certainly an underestimate” due to underreporting and the difficulty of establishing definitive attribution in complex medical cases.

“This safety signal has far-reaching implications for Americans, the U.S. pandemic response, and the agency itself,” he said in the correspondence.

Despite early international data showing a significantly heightened myocarditis risk in teenage boys and young adult men following mRNA vaccination, Prasad said U.S. authorities were slow to adjust guidance:

“They did not quickly attempt mitigation strategies such as spacing doses apart, lowering doses, [or] omitting doses among those with prior COVID-19.”

Myocarditis — inflammation of the heart muscle — can cause chest pain, cardiac arrest, and in severe cases, death.

Prasad further argued that by delaying acknowledgment of these concerns until after authorizing shots for boys 12 to 15, federal officials may have subjected lower-risk children to avoidable harm.

The Biden administration approved Pfizer’s vaccine for children ages 5–11 in November 2021 and expanded access to children under 5 in 2022. At the time, President Biden maintained the vaccines were “safe, highly effective,” and would give parents “peace of mind.”

Prasad’s letter paints a different picture in hindsight:

“Healthy young children who faced tremendously low risk of death were coerced…to receive a vaccine that could result in death.”

The FDA has not yet publicly clarified how it will communicate these findings to families, nor how the revelations may influence ongoing vaccine recommendations for children.

While the investigation continues, the internal report intensifies a national reckoning: whether pandemic-era mandates and messaging sufficiently weighed risks for healthy minors at extremely low danger from the virus itself.